

# ChromaDex Corporation Reports Third Quarter 2018 Financial Results

*- Third Quarter 2018 Net Revenues Increased by 33% to \$8.1 Million -*

## **Third Quarter 2018 Highlights vs. Third Quarter 2017**

- Net sales up 33%, fueled by growth of TRU NIAGEN<sup>®</sup>, which increased by 97%;
- TRU NIAGEN sales at 84% of NIAGEN-related sales, up from 60%
- Gross profit as a percentage of net sales improved by 580 basis points to 53.7%;
- Launched TRU NIAGEN PRO (60ct, 300mg per capsule), the highest dose of NR in a single capsule;
- Earned certification from NSF International Certified for Sport program; and
- Signed MOU for creation of a strategic partnership for aging research in Jiangxi Province, China

LOS ANGELES, Nov. 07, 2018 — ChromaDex Corp. (NASDAQ:CDXC) today reported third quarter 2018 financial results.

“I’m encouraged by the progress we made in the third quarter and remain enthusiastic about the future, TRU NIAGEN continued to show dramatic growth and we are building a platform and brand for strong future growth,” said Rob Fried, Chief Executive Officer.

## **Results of operations for the three months ended September 30, 2018**

For the three months ended September 30, 2018 (“Q3 2018”), ChromaDex reported net sales of \$8.1 million, up 33% compared to \$6.1 million from continuing operations in the third quarter of 2017 (“Q3 2017”). The increase in third quarter revenues was driven by growth in sales of TRU NIAGEN.

Gross margin as a percentage of sales improved by 580 basis points to 53.7% for Q3 2018 compared to 47.9% for Q3 2017. We experienced better gross margins due to the positive impact of TRU NIAGEN consumer product sales, which we anticipate will continue.

Operating expenses were \$13.0 million in the third quarter of 2018, compared to \$6.1 million from continuing operations in the same period for 2017. The increase of \$6.9 million in operating expenses for third quarter was the result of the Company’s strategic decision to invest \$3.7 million more in advertising and marketing to build out the TRU NIAGEN brand, as well as higher R&D expenses of \$0.3 million, higher legal costs of \$1.2 million, and higher stock-based compensation expense of \$0.6 million. Excluding legal and equity-based compensation expenses, general and administrative expenses were \$3.0 million, up by \$1.1 million as compared to the prior year.

The net loss for the third quarter of 2018 was \$8.6 million or (\$0.16) per share as compared

to a net loss from continuing operations of \$3.2 million or (\$0.07) per share for Q3 2017.

For the third quarter of 2018, the reported loss was negatively impacted by a non-cash charge of \$1.3 million related to stock-based compensation.

Adjusted EBITDA, a non-GAAP measure, was (\$7.1) million for Q3 2018, compared to adjusted EBITDA from continuing operations of (\$2.5) million for Q3 2017. ChromaDex defines Adjusted EBITDA as net income (loss) adjusted for income tax, interest, depreciation, amortization and non-cash stock compensation costs. The Basic and Diluted Adjusted EBITDA per share for Q3 2018 was (\$0.13) versus (\$0.05) from continuing operations for Q3 2017.

In the first nine months of 2018, the net cash used in operating activities was \$15.8 million versus \$6.0 million in the prior year. The Company ended the third quarter of 2018 with a solid balance sheet with cash of \$28.2 million.

### **Outlook**

Looking forward, the Company expects the revenue growth to be driven by our U.S. ecommerce and Watsons' international business, as well as the launch of TRU NIAGEN® in certain new international markets. The Company will continue to invest efficiently in marketing expenditures to build out the TRU NIAGEN brand and new capabilities to support growth. In addition, as necessary, we will continue to invest in legal costs to protect our intellectual property.

We continue to expect working capital to be a positive source of cash of \$3 to \$5 million for the full year, as we expect our net losses to moderate in the fourth quarter and we continue to tightly manage working capital for the balance of the year.

### **Investor Conference Call**

ChromaDex management will host an investor conference call to discuss the year end results and provide a general business update on Thursday, November 7, at 4:30pm ET.

Participants should call in at least 10 minutes prior to the call. The dial-in information is as follows:

Date: Thursday, November 7, 2018

Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)

Toll-free dial-in number: (866) 327-8118

International dial-in number: (678) 509-7526

Conference ID: 7066529

Webcast link: <https://edge.media-server.com/m6/p/uofko2ym>

The webcast replay will be available after the completion of the call on the Investor Relations section of the Company website, [www.chromadex.com](http://www.chromadex.com).

The earnings press release, and its accompanying financial exhibits, will be available on the Investor Relations section of the Company website, [www.chromadex.com](http://www.chromadex.com).

### **About Non-GAAP Financial Measures**

ChromaDex's non-GAAP financial measures exclude interest, tax, depreciation, amortization and share-based compensation for adjusted EBITDA. ChromaDex used these non-GAAP measures when evaluating its financial results as well as for internal resource management, planning and forecasting purposes. These non-GAAP measures should not be viewed in isolation from or as a substitute for ChromaDex's financial results in accordance with GAAP. Reconciliation of GAAP to non-GAAP measures are attached to this press release.

### **About ChromaDex:**

ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN<sup>®</sup> nicotinamide riboside, sold directly to consumers as TRU NIAGEN<sup>®</sup>, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN is helping the world AGE BETTER<sup>®</sup>. ChromaDex maintains a website at [www.ChromaDex.com](http://www.ChromaDex.com) to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

### **Important Note on Forward Looking Statements:**

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include the quotation from ChromaDex's Chief Executive Officer, and statements related to future, revenue growth being driven by ChromaDex's U.S. ecommerce and Watsons' international business, launching TRU NIAGEN in certain new international markets, whether the Company will continue to invest in marketing to build out the TRU NIAGEN brand and legal expenditures to protect ChromaDex's intellectual property, and the expectations of future working capital, cash flow and net loss. Other risks that contribute to the uncertain nature of the forward-looking statements are reported in our most recent Forms 10-Q and 10-K as filed with the SEC. Readers are cautioned not to place undue

reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

**ChromaDex Investor Relations Contact:**

Brianna Gerber, Sr. Director of FP&A and Investor Relations

(949) 344-3782

[briannag@chromadex.com](mailto:briannag@chromadex.com)

**ChromaDex Media Contact:**

Alex Worsham, Director of Strategic Partnerships

(949) 648-3775

[alexw@chromadex.com](mailto:alexw@chromadex.com)

**ChromaDex Corporation and Subsidiaries**

**Condensed Consolidated Statements of Operations**

**For the Three Month Periods Ended September 30, 2018 and September 30, 2017**

**(In thousands, except per share data)**

	<b>Sep. 30, 2018</b>	Sep. 30, 2017
Sales, net	\$ <b>8,120</b>	\$ 6,084
Cost of sales	<b>3,759</b>	3,169
<b>Gross profit</b>	<b>4,361</b>	2,915
Operating expenses:		
Sales and marketing	<b>4,837</b>	1,103
Research and development	<b>1,350</b>	1,040
General and administrative	<b>6,770</b>	3,948
<b>Operating expenses</b>	<b>12,957</b>	6,091
<b>Operating loss</b>	<b>(8,596)</b>	(3,176)
Nonoperating expense:		
Interest expense, net	<b>(9)</b>	(45)
<b>Nonoperating expenses</b>	<b>(9)</b>	(45)
<b>Loss from continuing operations</b>	<b>(8,605)</b>	(3,221)
Loss from discontinued operations	-	(109)
Gain on sale of discontinued operations	-	5,467

<b>Income from discontinued operations</b>	-	5,358
<b>Net (loss) income</b>	<b>\$ (8,605)</b>	<b>\$ 2,137</b>
Basic (loss) earnings per common share:		
Loss from continuing operations	<b>\$ (0.16)</b>	<b>\$ (0.07)</b>
Earnings from discontinued operations	<b>\$ -</b>	<b>\$ 0.12</b>
Basic (loss) earnings per common share	<b>\$ (0.16)</b>	<b>\$ 0.05</b>
Diluted (loss) earnings per common share:		
Loss from continuing operations	<b>\$ (0.16)</b>	<b>\$ (0.07)</b>
Earnings from discontinued operations	<b>\$ -</b>	<b>\$ 0.11</b>
Diluted (loss) earnings per common share	<b>\$ (0.16)</b>	<b>\$ 0.04</b>
Basic weighted average common shares outstanding	<b>55,068</b>	47,065
Diluted weighted average common shares outstanding	<b>55,068</b>	47,557

See Notes to Consolidated Financial Statements.

See Notes to Condensed Consolidated Financial Statements in Part I of ChromaDex's Quarterly Report

on Form 10-Q filed with Securities and Exchange Commission on November 7, 2018.

**ChromaDex Corporation and Subsidiaries**  
**Condensed Consolidated Balance Sheets**  
**September 30, 2018 and December 30, 2017**  
**(In thousands, except per share data)**

	<b>Sep. 30, 2018</b>	Dec. 30, 2017
<b>Assets</b>		
Current Assets		
Cash	<b>\$ 28,214</b>	\$ 45,389
Trade receivables, net of allowances of \$0.5 million and \$0.7 million, respectively;		
Receivables from Related Party: \$0.7 million and \$1.5 million, respectively	<b>4,773</b>	5,338
Contract assets	<b>76</b>	-
Receivable held at escrow	<b>752</b>	-
Inventories	<b>7,079</b>	5,796
Prepaid expenses and other assets	<b>593</b>	655
<b>Total current assets</b>	<b>41,487</b>	57,178
Leasehold Improvements and Equipment, net	<b>3,745</b>	2,872
Deposits	<b>269</b>	272
Receivable Held at Escrow	<b>-</b>	750
Intangible Assets, net	<b>1,521</b>	1,652
<b>Total assets</b>	<b>\$ 47,022</b>	<b>\$ 62,724</b>

**Liabilities and Stockholders' Equity**

Current Liabilities

Accounts payable	\$ 8,893	\$ 3,719
Accrued expenses	3,587	3,645
Current maturities of capital lease obligations	183	196
Contract liabilities and customer deposits	155	314
Deferred rent, current	142	114
Due to officer	-	100
<b>Total current liabilities</b>	<b>12,960</b>	<b>8,088</b>
Capital Lease Obligations, Less Current Maturities	178	310
Deferred Rent, Less Current	482	492
<b>Total liabilities</b>	<b>13,620</b>	<b>8,890</b>
Commitments and Contingencies		
Stockholders' Equity		
Common stock, \$.001 par value; authorized 150,000 shares; issued and outstanding September 30, 2018 54,919 shares and December 30, 2017 54,697 shares	55	55
Additional paid-in capital	114,882	110,380
Accumulated deficit	(81,535)	(56,601)
<b>Total stockholders' equity</b>	<b>33,402</b>	<b>53,834</b>
<b>Total liabilities and stockholders' equity</b>	<b>\$ 47,022</b>	<b>\$ 62,724</b>

See Notes to Condensed Consolidated Financial Statements in Part I of ChromaDex's Quarterly Report

on Form 10-Q filed with Securities and Exchange Commission on November 7, 2018.

### **Consolidated Statements of Operations, Unaudited (US GAAP)**

**Three Months Ended Sep. 30, 2018 and Sep. 30, 2017**

**(In thousands, except per share data)**

	Q3 2018	Q3 2017
Sales, net	\$ 8,120	\$ 6,084
Cost of sales	3,759	3,169
<b>Gross profit</b>	<b>4,361</b>	<b>2,915</b>
Operating expenses:		
Sales and marketing	4,837	1,103
Research and development	1,350	1,040
General and administrative	6,770	3,948
<b>Operating expenses</b>	<b>12,957</b>	<b>6,091</b>
<b>Operating loss</b>	<b>(8,596)</b>	<b>(3,176)</b>
Nonoperating expense:		
Interest expense, net	(9)	(45)
<b>Nonoperating expenses</b>	<b>(9)</b>	<b>(45)</b>
<b>Loss from continuing operations</b>	<b>(8,605)</b>	<b>(3,221)</b>
Loss from discontinued operations	-	(109)

Gain on sale of discontinued operations	-	5,467
<b>Income from discontinued operations</b>	-	5,358
<b>Net (loss) income</b>	<b>\$ (8,605)</b>	<b>\$ 2,137</b>
Basic (loss) earnings per common share:		
Loss from continuing operations	<b>\$ (0.16)</b>	<b>\$ (0.07)</b>
Earnings from discontinued operations	<b>\$ -</b>	<b>\$ 0.12</b>
Basic (loss) earnings per common share	<b>\$ (0.16)</b>	<b>\$ 0.05</b>
Diluted (loss) earnings per common share:		
Loss from continuing operations	<b>\$ (0.16)</b>	<b>\$ (0.07)</b>
Earnings from discontinued operations	<b>\$ -</b>	<b>\$ 0.11</b>
Diluted (loss) earnings per common share	<b>\$ (0.16)</b>	<b>\$ 0.04</b>
Basic weighted average common shares outstanding	<b>55,068</b>	47,065
Diluted weighted average common shares outstanding	<b>55,068</b>	47,557

**Effects of Charges associated with Interest, Tax, Depreciation,  
Amortization and Share-based Compensation Expense  
Three Months Ended Sep. 30, 2018 and Sep. 30, 2017  
(In thousands, except per share data)**

	<b>Q3 2018</b>	<b>Q3 2017</b>
Sales, net	<b>\$ -</b>	<b>\$ -</b>
Cost of sales	<b>(95)</b>	(47)
<b>Gross profit</b>	<b>95</b>	47
Operating expenses:		
Sales and marketing	<b>(108)</b>	-
Research and development	<b>(178)</b>	-
General and administrative	<b>(1,164)</b>	(590)
<b>Operating expenses</b>	<b>(1,450)</b>	(590)
<b>Operating income</b>	<b>1,545</b>	637
Nonoperating income:		
Interest expense, net	<b>9</b>	45
<b>Nonoperating income</b>	<b>9</b>	45
<b>Income from continuing operations</b>	<b>1,554</b>	682
Income from discontinued operations	-	49
Gain on sale of discontinued operations	-	-
<b>Income from discontinued operations</b>	<b>-</b>	49
<b>Effects of adjusted EBITDA</b>	<b>\$ 1,554</b>	<b>\$ 731</b>
Basic earnings per common share:		
Earnings from continuing operations	<b>\$ 0.03</b>	<b>\$ 0.01</b>
Earnings from discontinued operations	<b>\$ -</b>	<b>\$ 0.00</b>
Basic earnings per common share	<b>\$ 0.03</b>	<b>\$ 0.02</b>
Diluted earnings per common share:		
Earnings from continuing operations	<b>\$ 0.03</b>	<b>\$ 0.01</b>

Earnings from discontinued operations	\$	-	\$	0.00
Diluted earnings per common share	\$	<b>0.03</b>	\$	0.02
Basic weighted average common shares outstanding		<b>55,068</b>		47,065
Diluted weighted average common shares outstanding		<b>55,068</b>		47,557

**Consolidated Statements of Operations, Adjusted EBITDA  
Excluding Interest, Tax, Depreciation, Amortization and  
Share-based Compensation (Non-GAAP Presentation)  
Three Months Ended Sep. 30, 2018 and Sep. 30, 2017  
(In thousands, except per share data)**

		<b>Q3 2018</b>		<b>Q3 2017</b>
Sales, net	\$	<b>8,120</b>	\$	6,084
Cost of sales		<b>3,664</b>		3,122
<b>Gross profit</b>		<b>4,456</b>		2,962
Operating expenses:				
Sales and marketing		<b>4,729</b>		1,103
Research and development		<b>1,172</b>		1,040
General and administrative		<b>5,606</b>		3,358
<b>Operating expenses</b>		<b>11,507</b>		5,501
<b>Operating loss</b>		<b>(7,051)</b>		(2,539)
Nonoperating expense:				
Interest expense, net		-		-
<b>Nonoperating expenses</b>		-		-
<b>Loss from continuing operations</b>		<b>(7,051)</b>		(2,539)
Loss from discontinued operations		-		(60)
Gain on sale of discontinued operations		-		5,467
<b>Income from discontinued operations</b>		-		5,407
<b>Adjusted EBITDA</b>	\$	<b>(7,051)</b>	\$	2,868
Basic (loss) earnings per common share:				
Loss from continuing operations	\$	<b>(0.13)</b>	\$	(0.05)
Earnings from discontinued operations	\$	-	\$	0.11
Basic (loss) earnings per common share	\$	<b>(0.13)</b>	\$	0.06
Diluted (loss) earnings per common share:				
Loss from continuing operations	\$	<b>(0.13)</b>	\$	(0.05)
Earnings from discontinued operations	\$	-	\$	0.11
Diluted (loss) earnings per common share	\$	<b>(0.13)</b>	\$	0.06
Basic weighted average common shares outstanding		<b>55,068</b>		47,065
Diluted weighted average common shares outstanding		<b>55,068</b>		47,557